Table. Baseline Clinical, Oncological, Laboratory, and Cardiovascular Magnetic Resonance (CMR) Characteristics of the Entire Study Cohort and Patients With and Without Cancer Therapy–Related Cardiac Dysfunction (CTRCD).
| Characteristic | No. (%) | P value | ||
|---|---|---|---|---|
| All patients (N = 136) | No CTRCD (n = 99) | CTRCD (n = 37) | ||
| Age, mean (SD), y | 51.1 (9.2) | 50.5 (9.0) | 52.6 (9.8) | .25 |
| Race | ||||
| Asian | 50 (37) | 37 (37) | 13 (35) | .34 |
| Black | 4 (3) | 2 (2) | 2 (5) | |
| Non-Black Hispanic | 6 (4) | 3 (3) | 3 (8) | |
| White | 76 (56) | 57 (58) | 19 (51) | |
| Blood pressure, mean (SD), mm Hg | ||||
| Systolic | 118 (16) | 117 (16) | 119 (16) | .41 |
| Diastolic | 75 (10) | 74 (9) | 78 (11) | .08 |
| Heart rate, mean (SD), bpm | 66 (9) | 65 (8) | 69 (11) | .09 |
| Diabetes | 5 (3.7) | 2 (2.0) | 3 (8.1) | .12 |
| Hypertension | 21 (15.4) | 16 (16.2) | 5 (13.5) | .80 |
| Dyslipidemia | 14 (10.3) | 6 (6.1) | 8 (21.6) | .02 |
| Smoking | 33 (24.3) | 21 (21.2) | 12 (32.4) | .18 |
| Baseline medications | ||||
| ACE inhibitor | 6 (4.4) | 3 (3.0) | 3 (8.1) | .34 |
| Angiotensin receptor blocker | 7 (5.1) | 7 (7.1) | 0 (0.0) | .19 |
| β-Blocker | 7 (5.1) | 5 (5.1) | 2 (5.4) | <.99 |
| Statin | 9 (6.6) | 4 (4.0) | 5 (13.5) | .06 |
| Any cardiac medication | 22 (16.2) | 14 (14.1) | 8 (21.6) | .30 |
| Breast cancer stage | .53 | |||
| 1 | 16 (11.8) | 12 (12.1) | 4 (10.8) | |
| 2 | 81 (59.6) | 60 (60.6) | 21 (56.8) | |
| 3 | 38 (27.9) | 27 (27.3) | 11 (29.7) | |
| 4a | 1 (0.7) | 0 (0.0) | 1(2.7) | |
| Breast cancer side | .84 | |||
| Left | 79 (58.1) | 56 (56.6) | 23 (23.2) | |
| Right | 55 (40.4) | 41 (41.4) | 14 (37.8) | |
| Bilateral | 2 (1.5) | 2 (2.0) | 0 (0) | |
| CMR measures, mean (SD) | ||||
| LVEDV, mL | 128.1 (22.4) | 127.1 (20.3) | 130.8 (27.4) | .45 |
| LVEDV indexed, mL/m2 | 74.4 (11.6) | 74.5 (11.0) | 74.2 (13.3) | .88 |
| LVESV, mL | 47.5 (10.7) | 46.7 (9.9) | 49.5 (12.4) | .21 |
| LVESV indexed, mL/m2 | 27.6 (5.8) | 27.4 (5.5) | 28.1 (6.4) | .54 |
| LVEF, % | 63.2 (4.0) | 63.4 (4.0) | 62.4 (4.0) | .17 |
| LV mass index, g/m2 | 35.9 (6.0) | 36.2 (6.2) | 35.2 (5.4) | .37 |
| GLS, % | 18.5 (1.9) | 18.8 (1.9) | 17.8 (1.8) | .01 |
| GCS, % | 20.7 (2.1) | 20.9 (2.0) | 20.0 (2.1) | .03 |
| EGEr, median (IQR) | 1.95 (1.55-2.69) | 1.89 (1.55-2.60) | 2.06 (1.72-2.85) | .33 |
| T1, milliseconds | 1012.0 (26.4) | 1013.1 (25.7) | 1009.0 (28.5) | .45 |
| T2, milliseconds | 51.4 (2.2) | 51.5 (2.1) | 51.0 (2.3) | .24 |
| ECV, % | 25.3 (2.4) | 25.4 (2.4) | 24.9 (2.6) | .30 |
| Indexed ECV, mL/m2 | 8.7 (1.7) | 8.8 (1.7) | 8.4 (1.7) | .25 |
| Indexed ICV, mL/m2 | 25.6 (4.5) | 25.8 (4.7) | 25.2 (3.8) | .46 |
| Serum biomarkers, mean (SD) | ||||
| BNP level, pg/mL | 21.0 (13.8) | 21.1 (12.8) | 20.9 (16.4) | .96 |
| hs-cTnI Level, ng/L | 3.3 (3.8) | 3.7 (4.4) | 2.0 (1.0) | .001 |
Abbreviations: ACE, angiotensin-converting enzyme inhibitor; BNP, B-type natriuretic peptide; bpm, beats per minute; ECV, extracellular volume fraction; EGEr, early gadolinium enhancement ratio; GCS, global circumferential strain; GLS, global longitudinal strain; hs-cTnI, high-sensitivity cardiac troponin I; ICV, intracellular volume; LV, left ventricular; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume.
a
One patient had stage 3 disease at study enrollment, but early during treatment was found to have solitary metastasis to the liver. She continued the same cancer regimen and therefore was kept in the study.